Abstract
Currently Portugal is still on the EU ending tale of access to innovative medicines, with an average time to availability of 641 days as per the WAIT report, published by EFPIA. With 255 reimbursement submissions reviewed from 2017 to 31st of May 2021, distributed by different therapeutic areas, the objective of this study is to analyze the impact of burden these diseases have to the rate of innovation in each therapeutic area (number of approvals and the average time to approval).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
